Empagliflozin 25mg + Metformin Hydrochloride (Extended Release) 1000 mg: Uses, Benefits, Dosage, Side Effects & Precautions
Empagliflozin 25mg + Metformin Hydrochloride (Extended Release) 1000 mg is a prescription combination medicine used to improve blood glucose control in adults with type 2 diabetes mellitus. GLIEMPAFLOZIN MET ER, marketed by Steris Healthcare, combines empagliflozin, an SGLT2 inhibitor, with extended-release metformin, a biguanide. The two medicines work through complementary pathways to reduce elevated blood glucose.
What is Empagliflozin 25mg + Metformin Hydrochloride (Extended Release) 1000 mg used for?
Empagliflozin 25mg + Metformin Hydrochloride (Extended Release) 1000 mg is used along with a suitable diet and regular physical activity to improve glycemic control in adults with type 2 diabetes when combination treatment is appropriate.
Empagliflozin reduces glucose reabsorption in the kidneys, causing more glucose to be eliminated in urine. Metformin ER primarily reduces glucose production by the liver and improves the body's sensitivity to insulin.
GLIEMPAFLOZIN MET ER is not a replacement for lifestyle management and is not intended for type 1 diabetes or diabetic ketoacidosis treatment.
Why it's important
Long-term uncontrolled blood glucose can increase the risk of cardiovascular disease, kidney disease, nerve damage, vision problems, and other diabetes-related complications.
This combination provides two distinct mechanisms for glucose control. Metformin addresses excessive hepatic glucose production, while empagliflozin promotes urinary glucose elimination.
Empagliflozin may also provide cardiovascular and kidney benefits in appropriately selected patients, depending on the patient's clinical profile and indication.
Because kidney function is important for the safe use of both components, healthcare professionals may assess renal function before and during treatment.
Key Benefits
What are the benefits?
When clinically appropriate, GLIEMPAFLOZIN MET ER may offer several therapeutic benefits:
- Helps lower elevated blood glucose.
- Supports improved HbA1c control as part of a comprehensive diabetes-management plan.
- Combines two complementary glucose-lowering mechanisms.
- Metformin reduces excessive glucose production by the liver.
- Empagliflozin increases glucose elimination through urine.
- Can help improve insulin sensitivity through the metformin component.
- May provide cardiovascular and renal benefits associated with empagliflozin in eligible patients.
- Extended-release metformin may provide a convenient once-daily formulation for suitable patients.
The degree of benefit varies according to baseline glucose levels, kidney function, adherence, diet, exercise, and other diabetes treatments.
Side Effects
Some patients may experience side effects, particularly when beginning treatment.
Potential side effects include:
- Nausea
- Diarrhea
- Abdominal discomfort
- Reduced appetite
- Increased urination
- Increased thirst
- Genital fungal infections
- Urinary tract infections
- Headache
- Dehydration
- Changes in bowel habits
Gastrointestinal symptoms are commonly associated with metformin and may become less noticeable as the body adjusts.
Because empagliflozin increases urinary glucose and fluid excretion, maintaining appropriate hydration is important unless fluid restriction has been medically advised.
Serious Side Effects
Although uncommon, both components have important safety considerations.
Lactic acidosis is a rare but potentially serious complication associated with metformin. The risk is increased in certain circumstances, including significant kidney impairment and severe conditions associated with reduced tissue oxygenation.
Possible warning symptoms include:
- Severe weakness
- Unusual tiredness or sleepiness
- Rapid or difficult breathing
- Persistent vomiting
- Severe abdominal discomfort
- Confusion
Empagliflozin can rarely be associated with diabetic ketoacidosis (DKA), including situations where blood glucose is not extremely high. Warning symptoms can include nausea, vomiting, abdominal pain, unusual fatigue, and difficulty breathing.
Severe dehydration, prolonged fasting, significant illness, excessive alcohol consumption, or inadequate insulin availability can increase DKA risk.
Seek urgent medical attention if severe symptoms occur.
Available Substitute
There is no single substitute that is suitable for every patient.
Depending on the individual's diabetes control, kidney function, cardiovascular risk, weight, current medicines, and treatment goals, a healthcare professional may consider:
- Empagliflozin with a different metformin strength
- Another SGLT2 inhibitor combined with metformin
- Metformin ER alone
- Another oral glucose-lowering combination
- GLP-1 receptor agonist-based treatment
- Other individualized diabetes therapies
Different formulations and strengths are not automatically interchangeable. A substitute should be selected by a qualified healthcare professional.
Dosage Guidelines
Take GLIEMPAFLOZIN MET ER exactly as prescribed.
This strength contains empagliflozin 25 mg and metformin hydrochloride extended-release 1000 mg. It may be appropriate as a maintenance strength for selected patients who are already receiving and tolerating the individual components at suitable doses.
The dose should be individualized based on glycemic control, previous treatment, kidney function, and tolerability.
Because the metformin component is extended release, the tablet should generally be swallowed whole with water and should not be crushed, split, or chewed unless the specific product labeling permits it.
Taking the medicine with food may help reduce gastrointestinal discomfort.
If a dose is missed, follow your healthcare professional's instructions. Do not take two doses together to compensate.
Precautions & Warnings
Before using GLIEMPAFLOZIN MET ER, tell your healthcare professional if you have:
- Kidney disease or reduced kidney function
- Liver disease
- Heart failure
- Recurrent urinary or genital infections
- A history of diabetic ketoacidosis
- Severe dehydration
- Conditions associated with reduced tissue oxygenation
- Heavy or excessive alcohol consumption
- A planned surgery or prolonged fasting
Kidney function should be assessed because renal impairment can affect treatment suitability and safety.
Empagliflozin may increase fluid loss and can contribute to low blood pressure, particularly in older adults, people taking diuretics, or individuals who are dehydrated.
Healthcare professionals may recommend temporarily withholding treatment during certain situations, such as prolonged fasting, major surgery, or severe acute illness.
Tell your doctor about all prescription medicines, over-the-counter medicines, supplements, and other diabetes treatments you use.
How to Use
Use GLIEMPAFLOZIN MET ER according to the prescribed schedule.
Take the tablet with food if instructed, and swallow the extended-release formulation whole with water.
Maintain adequate fluid intake unless your doctor has recommended fluid restriction. Monitor blood glucose according to your individualized diabetes-management plan.
Do not discontinue diabetes medication simply because you feel well. Type 2 diabetes can remain uncontrolled without obvious symptoms.
If you develop persistent vomiting, severe abdominal pain, unusual weakness, breathing difficulty, or symptoms suggestive of ketoacidosis, seek urgent medical evaluation.
Mechanism of Action
Empagliflozin Mechanism of Action
Empagliflozin is an SGLT2 inhibitor.
SGLT2 is responsible for reabsorbing filtered glucose in the proximal renal tubules. Empagliflozin inhibits SGLT2, reducing glucose reabsorption and increasing urinary glucose excretion.
This lowers blood glucose and also produces an osmotic diuretic effect, which can increase urine volume.
SGLT2 inhibition can also influence renal hemodynamics and cardiovascular pathways, contributing to the cardiovascular and kidney benefits observed with empagliflozin in appropriately selected patients.
Metformin ER Mechanism of Action
Metformin is a biguanide antidiabetic medicine. Its primary action is to reduce excessive glucose production by the liver.
It also improves peripheral insulin sensitivity and promotes glucose utilization. Metformin does not normally stimulate pancreatic insulin release, so when used alone it has a relatively low risk of causing hypoglycemia.
The extended-release formulation is designed to release metformin gradually over time.
Combined Mechanism
The combination works through complementary pathways:
Reduced hepatic glucose production + increased urinary glucose elimination + improved insulin sensitivity.
This multimodal approach can provide effective glycemic control for appropriately selected adults with type 2 diabetes.
Conclusion
Empagliflozin 25mg + Metformin Hydrochloride (Extended Release) 1000 mg, marketed as GLIEMPAFLOZIN MET ER by Steris Healthcare, combines two established glucose-lowering medicines with complementary mechanisms of action.
Metformin ER primarily reduces glucose production by the liver and improves insulin sensitivity, while empagliflozin increases urinary glucose elimination through SGLT2 inhibition. Together, they can support improved blood glucose and HbA1c control alongside appropriate diet, physical activity, and regular medical follow-up.
Because this combination can affect kidney function, hydration, and metabolic balance, it should be used under medical supervision. Patients should understand the warning signs of dehydration, diabetic ketoacidosis, and metformin-associated lactic acidosis and seek medical attention when serious symptoms occur.
GLIEMPAFLOZIN MET ER should be taken exactly as prescribed, and the extended-release tablet should not be crushed or chewed unless specifically permitted by the product instructions.
Comments
Post a Comment